

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/09		SERIAL NO. 09/765,151	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Gilbert R. Gonzales et al.			
				FILING DATE January 17, 2001		GROUP 3751	

JUL 14 2003  
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)		
AR A.L	WO 0037114	06/29/00	International		N/A		
AR A.M	WO 9917747	04/15/99	International		N/A		
AR A.N	WO 9512812	05/11/95	International		N/A		
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)	
A.R	Cerrato et al., <u>Marking of Naltrexone and Placebo Capsules with Riboflavin as an Indicator of Compliance</u> , Farmacia Clinica, Vol. 6, No. 10, 1989, pp. 758-760
A.S	Del Boca et al., <u>Assessment of Medication Compliance in Alcoholics Through UV Light Detection of a Riboflavin Tracer</u> , Alcoholism, Clinical and Experimental Research, United States, November, 1996, Vol. 20, No. 8, pp. 1412-1417
A.T	International Search Report, PCT/US02/01167, May 6, 2003.

EXAMINER <i>Anuradha Ramare</i>	DATE CONSIDERED 8/13/03
------------------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

RECEIVED

JUL 17 2003

TECHNOLOGY CENTER R3700